Abstracts tagged "autoimmune diseases"

Abstract Number: 0008 • ACR Convergence 2022
CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow
Jennifer Barnas¹, Diana Alzamareh², Nida Meednu² and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: CD11c+ age/autoimmunity-associated B cells (ABC) are associated with autoantibody producing cells and disease flare in systemic lupus erythematosus. ABC were initially identified in aged…
Abstract Number: 0140 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Müller⁶, Carl Coeck⁷, Klaus Rohr⁸ and Wim Wuyts⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim SComm, Brussels, Brussels, Belgium, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital…
Abstract Number: 0359 • ACR Convergence 2022
Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
Ronald Van Vollenhoven¹, Eric F. Morand², Richard A. Furie³, Ian N. Bruce⁴, Gabriel Abreu⁵, Raj Tummala⁶, Hussein Al-Mossawi⁷ and Catharina Lindholm⁸, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, University of Amsterdam, Amsterdam, Netherlands, ²Monash University, Melbourne, Australia, ³Northwell Health, Great Neck, NY, ⁴The University of Manchester, Manchester, United Kingdom, ⁵AstraZeneca, Mölndal, Sweden, ⁶AstraZeneca, Gaithersburg, MD, ⁷AstraZeneca, Cambridge, United Kingdom, ⁸AstraZeneca, Gothenburg, Sweden
Background/Purpose: In patients with SLE, achieving remission is a treat-to-target goal. Remission is associated with lower rates of hospitalization and damage accrual and better quality…
Abstract Number: 0635 • ACR Convergence 2022
Blood RNA-sequencing Reveals Complex Immune Dysregulation in ANA-positive Individuals with Distinct Profiles Preceding Progression to SLE versus Stable Autoimmunity
Lucy Marie Carter¹, Md Yuzaiful Md Yusof², Darren Plant³, Julien Bauer⁴, Stephanie Wenlock⁴, Adewonuola Alase¹, Antonios Psarras¹, Zoe Wigston¹ and Edward M Vital², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Anti-nuclear antibody (ANA) positivity represents a complex ‘At-Risk’ state for development of connective tissue disease (CTD). ANA may become positive years in advance of…
Abstract Number: 0717 • ACR Convergence 2022
Treatment Utilization in Dermatomyositis: An Analysis of Electronic Medical Records in the United States
Adrian Kielhorn¹, Zheng Wang¹, Kristin Moy¹, Lisa Christopher-Stine², Ingrid Lundberg³, Hector Chinoy⁴, Kaniah Gunter⁵ and Rohit Aggarwal⁶, ¹Alexion, AstraZeneca Rare Disease, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁴The University of Manchester, Sale, United Kingdom, ⁵Patient Author, Norfolk, VA, ⁶Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Dermatomyositis (DM) is a rare, chronic inflammatory disease characterized by skin manifestations and/or progressive muscle weakness and other systemic manifestations. Patients with DM were…
Abstract Number: 0772 • ACR Convergence 2022
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
Carina Soto-Fajardo¹, Angélica Peña Ayala², Fernanda Gonzalez², Paola Flores², Ana Cristina Medina², Araceli Bernal², Carlos Pineda², Olga-Lidia Vera-Lastra³ and Luis Javier Jara Quezada², ¹Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ³Centro Médico La Raza, Ciudad de México, Mexico
Background/Purpose: From January 2021 around 60% of the total population has received at least one dose of any COVID-19 vaccine. A minority of vaccinated individuals…
Abstract Number: 0935 • ACR Convergence 2022
Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
Giorgio CASABURI, Tyler O'Malley, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity. RA affects approximately 0.5/1% of adults in the…
Abstract Number: 1142 • ACR Convergence 2022
The Lupus Risk Allele Associated Xq28 Haplotype Identifies the Molecular Endotype of a Cohort of European SLE Patients with Enhanced IRAK1 Signaling
Rheyanna Clemens¹, Tyson Dawson¹, Katherine Owen², Amrie Grammer³ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²RILITE, Crozet, VA, ³AMPEL LLC, Charlottesville, VA
Background/Purpose: Previous genetic association studies identified a 9 gene region of Xq28 containing IRAK1 as a risk locus for SLE. IRAK1 plays key roles downstream…
Abstract Number: 1347 • ACR Convergence 2022
Poor Health-Related Quality of Life in Patients with Lupus Nephritis
Cristina Arriens¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) associated with considerable morbidity that has a devastating impact…
Abstract Number: 1630 • ACR Convergence 2022
Single-cell Profiling of B Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion
Aaron Wagner¹, Nida Meednu², Garrett Dunlap³, Fan Zhang⁴, Anna Jonsson⁵, Kevin Wei⁶, Ami Ben-artzi⁷, Lindsy Forbess⁸, Laura Geraldino-Pardilla⁹, Diane Horowitz¹⁰, Laura Hughes¹¹, Arthur Mandelin¹², Karen Salomon-Escoto¹³, Darren Tabechian¹⁴, Edward DiCarlo¹⁵, Ellen Gravallese¹⁶, Brendan Boyce¹⁷, Christopher Ritchlin¹⁸, James Lederer⁵, Mandy McGeachy¹⁹, Peter Gregersen²⁰, Paul Utz²¹, William Robinson²¹, Holden Maecker²¹, Judith James²², Joel Guthridge²², Harris Perlman²³, Joan Bathon⁹, Susan Goodman¹⁵, Gary S. Firestein²⁴, David Boyle²⁵, S. Louis Bridges, Jr.¹⁵, Kevin D Deane²⁶, V. Michael Holers²⁷, Larry Moreland²⁷, Andrew Filer²⁸, Costantino Pitzalis²⁹, Vivian Bykerk¹⁵, Laura Donlin¹⁵, Soumya Raychaudhuri⁵, Michael Brenner¹⁶, AMP RA/Lupus¹⁷, Deepak Rao⁵, Andrew McDavid¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical center, Rochester, NY, ³Harvard University, Boston, MA, ⁴University of Colorado, Aurora, CO, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Columbia University, New York, NY, ¹⁰Northwell Health, Jericho, NY, ¹¹University of Alabama at Birmingham, Birmingham, AL, ¹²Northwestern University Feinberg School of Medicine, Chicago, IL, ¹³University of Massachusetts Medical School, Worcester, MA, ¹⁴URMC, Rochester, NY, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁷University of Rochester, Rochester, ¹⁸Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹⁹University of Pittsburgh, Pittsburgh, PA, ²⁰The Feinstein Inst for Med Research, Larchmont, NY, ²¹Stanford University School of Medicine, Palo Alto, CA, ²²Oklahoma Medical Research Foundation, Oklahoma City, OK, ²³Northwestern University, Chicago, IL, ²⁴University of California, San Diego, San Diego, CA, ²⁵UCSD, La Jolla, CA, ²⁶University of Colorado Denver Anschutz Medical Campus, Denver, CO, ²⁷University of Colorado, Denver, CO, ²⁸University of Birmingham, Birmingham, United Kingdom, ²⁹Queen Mary University of London, London, United Kingdom
Background/Purpose: Ectopic lymphoid structures can develop in rheumatoid arthritis (RA) synovial tissue, but the precise pathways of B cell activation and selection are not well…
Abstract Number: 1841 • ACR Convergence 2022
To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis
María Paula Álvarez Hernández¹, Alfredo Madrid-García², Alejandro Gómez Gómez³, Lara Borrego Sanz⁴, Rosalía Méndez Fernández⁴, Pedro Arriola Villalobos⁴, Esperanza Pato Cour⁵, David Díaz Valle⁴ and Luis Rodriguez-Rodriguez⁵, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, Madrid, Spain, ³Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, ⁴Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, ⁵Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain
Background/Purpose: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed…
Abstract Number: 2184 • ACR Convergence 2022
CaMK4 Controls the Humoral Response via the T Follicular Helper Compartment and Regulates Autoimmunity
Marc Scherlinger¹, Hao Li², Wenliang Pan², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a dysregulated T cell compartment and production of autoantibodies leading to organ damage. We previously identified that…
Abstract Number: PP26 • ACR Convergence 2022
Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life
Catherine Ames¹, Courtney Wells² and Kristine Carandang¹, ¹Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ²University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN
Background/Purpose: What if Carrie Bradshaw, sex advice columnist, fashionsta, and all around icon from Sex and the City were chronically ill? Or disabled? That's the…
Abstract Number: 0009 • ACR Convergence 2022
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis
Xiaodong Wang, Mark Matijevic, Allen Poma, Shauna Quinn, Minggeng Gao, Lisa Crockett, Jessica Karnes, Keith Wilcoxen and Hua Mu, Zenas BioPharma, Waltham
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cell, CD19 expressing plasma cell, and plasmablast activity and is expected to provide clinical benefit across…
Abstract Number: 0146 • ACR Convergence 2022
Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis
Lara Sánchez-Bilbao¹, Javier Loricera², Santos Castañeda³, Clara Moriano⁴, F. Javier Narváez⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa⁹, Paloma Vela-Casampere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesús Carlos Fernández-López¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, Julio Sánchez-Martín¹, Mónica Calderón-Goercke¹, José Luis Hernández¹, Miguel Ángel González-Gay¹⁹ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis, including Giant Cell Arteritis (GCA). Clinical trials with TCZ in GCA were performed with intravenous (iv)…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].